非戈替尼治疗中重度活动性溃疡性结肠炎的长期安全性与疗效:SELECTION开放标签长期扩展研究长达4年随访的中期分析
SELECTIONLTE中期分析纳入SELECTION完成者250例和非应答者372例,随访至202周。非戈替尼200mg治疗者在第144周部分Mayo临床评分、生物标志物和健康相关生活质量缓解比例分别为80.0%、86.4%和86.0%,非应答者第192周分别为62.1%、76.7%和59.3%。不良事件发生率低,与既往分析一致。
要点
- 非戈替尼200mg治疗者在长期扩展研究中维持较高的症状、生物标志物和生活质量缓解比例。
- SELECTION第58周达到综合疾病控制的患者,至长期扩展第96周的部分Mayo临床评分、IBDQ和无激素部分Mayo临床评分缓解比例显著高于未达到者。
- 不良事件发生率低,与既往分析一致。
核心结论
- 非戈替尼可诱导并维持症状缓解、改善健康相关生活质量达4年。
- 安全性结果显示出经证实的长期获益-风险特征。
- 接受非戈替尼200mg治疗且达到综合疾病控制的患者长期结局优于未达到者。
研究设计与样本
- SELECTIONLTE为2b/3期SELECTION试验的开放标签长期扩展研究(NCT02914535)。
- SELECTION完成者(第10周对非戈替尼应答且完成维持研究)继续原分配治疗(双盲非戈替尼200mg或非戈替尼100mg)。
- SELECTION第10周无应答者接受开放标签非戈替尼200mg。
- 完成者250例、无应答者372例的数据报告至202周。
主要发现
- 非戈替尼200mg治疗完成者第144周部分Mayo临床评分、生物标志物和健康相关生活质量缓解比例分别为80.0%、86.4%和86.0%。
- 非戈替尼200mg治疗无应答者第192周部分Mayo临床评分、生物标志物和健康相关生活质量缓解比例分别为62.1%、76.7%和59.3%。
- SELECTION第58周达到综合疾病控制者至长期扩展第96周的部分Mayo临床评分、IBDQ和无激素部分Mayo临床评分缓解比例显著高于未达到者。
- 不良事件发生率低,与既往分析一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Filgotinib, an oral, once-daily, Janus kinase 1 preferential inhibitor, is an approved treatment for moderately to severely active ulcerative colitis. AIMS: The aim of this study is to assess the safety and efficacy of continued filgotinib therapy over ~4 years in the long-term extension of the phase 2b/3 SELECTION trial (SELECTIONLTE; NCT02914535). METHODS: In this interim analysis of SELECTIONLTE, SELECTION completers (week 10 responders to filgotinib who completed the maintenance study) continued their assigned treatment (double-blind filgotinib 200 mg [FIL200] or filgotinib 100 mg) and SELECTION week 10 non-responders received open-label FIL200. We assessed safety by adverse events (AEs), and efficacy by partial Mayo Clinic Score (pMCS), inflammatory biomarkers and health-related quality of life (HRQoL). We compared safety and efficacy between achievers and non-achievers of a multi-component endpoint, comprehensive disease control (CDC), comprising symptomatic, endoscopic, inflammatory biomarker and HRQoL improvements. RESULTS: Data for completers (n = 250) and non-responders (n = 372) were reported for ≤202 weeks. AE occurrences were low and consistent with previous analyses. The as-observed proportion of FIL200-treated patients in pMCS, biomarker and HRQoL remission during SELECTIONLTE remained high among completers (week 144: 80.0%, 86.4% and 86.0%, respectively) and increased among non-responders (week 192: 62.1%, 76.7% and 59.3%, respectively). Significantly higher proportions of CDC achievers at SELECTION week 58 achieved pMCS, IBDQ and corticosteroid-free pMCS remission than non-achievers, up to LTE week 96. CONCLUSIONS: Filgotinib induced and maintained symptomatic remission and improved HRQoL over 4 years. Safety results showed a proven long-term benefit-risk profile. FIL200-treated CDC achievers had better long-term outcomes than non-achievers.
引用
- Feagan BG, Matsuoka K, Rogler G, et al. Long-term safety and efficacy of filgotinib for the treatment of moderately to severely active ulcerative colitis: Interim analysis from up to 4 years of follow-up in the SELECTION open-label long-term extension study. Aliment Pharmacol Ther. 2024. PMID: 39086130. doi:10.1111/apt.18158
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。